Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/20/2006
 
First Published:
2/21/2003
1.
Phase III Randomized Study of Neoadjuvant Releasing Factor Agonist Therapy and Antiandrogen Therapy With or Without Docetaxel And Estramustine in Patients With Locally Advanced Prostate Cancer or With A High Risk of Relapse
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 80
Other
FRE-FNCLCC-GETUG-12/0203
EU-20238, NCT00055731
Last Modified:
1/14/2009
 
First Published:
1/25/2006
2.
Phase III Randomized Study of Androgen Suppression (AS) and Radiotherapy (RT) Versus AS and RT Followed by Docetaxel and Prednisone in Patients With Localized, High-Risk Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
RTOG-0521
NCT00288080
Last Modified:
1/13/2009
 
First Published:
5/11/2006
3.
Phase III Randomized Study of Zoledronate in Preventing Osteoporosis and Associated Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiotherapy and Luteinizing Hormone-Releasing Hormone Agonist Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Active
18 and over
NCI
RTOG-0518
0518, NCT00329797
Last Modified:
1/6/2009
 
First Published:
3/31/2008
4.
Phase III Randomized Study of Androgen Suppression Therapy and Radiotherapy With Versus Without Docetaxel in Patients With High-Risk Localized Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Not specified
NCI
CAN-NCIC-PR12
PR12, NCT00651326
5.
Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
R04-0092
NCT00138918
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute